Europe: 4,327 million USD (2030 value); CAGR: 18.1%
Isoxazoline is a relatively new chemical family of five-membered heterocyclic chemical compounds with one oxygen and one nitrogen atom next to each other. Isoxazoline compounds such as fluralaner, afoxolaner, sarolaner, and lotilaner are active components in tick repellents.
Ticks are non-flying insects that are parasites on dogs, cats, and other animals. The host must come into direct touch with a tick in order to become a parasite. Ticks are dangerous to pets because they transmit illnesses such as Lyme disease, Rocky Mountain spotted fever, ehrlichiosis, tularaemia, and STARI (Southern tick-associated rash illness). In order for illnesses to be transferred, a tick must remain attached to a host for several hours. To prevent pets against tick bites, a variety of repellents, insecticides, and growth inhibitors are commercially available.
The isoxazoline class of medicines are oral insecticides that have been approved for the treatment of ectoparasites in companion animals such as dogs and cats. These medications were initially introduced in 2013 as veterinary treatments for ticks and fleas in dogs. Several studies, however, have demonstrated their effectiveness against various veterinary and agricultural parasites. Bravecto, Credlio, Nexgard, and Simparica are examples of FDA-approved isoxazoline medications.
Innovations on current medications for new indications in oral and topical formulations, as well as increased awareness of ectoparasite prevention and control of fleas and ticks, are expected to drive market expansion. The market is divided into three sections: product type, pet kind, and geography.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
There has been an increase in pet animal care spending in recent years. The American Pet Products Association, Inc. (APPA) claims that "In 2019, the US Pet Industry spent a total of USD 97.1 billion. Similarly, the US Pet Industry Expenditure in 2020 was USD 103.6 billion. In 2020, USD 31.4 billion was spent on veterinary care and product sales, with a projected USD 32.2 billion in 2021."
Ticks and fleas are common parasites in pets like dogs and cats. Several commercially available medications can help dogs and cats avoid and control tick and flea infestations. The market for isoxazoline, a new family of ectoparasite medications for dogs and cats, is increasing. The key element driving demand for isoxazoline medications is growing spending on pet care and increased pet adoption.
Tick and flea prevention and control products are available on the market. The Environmental Protection Agency and the US Food and Drug Administration regulate some of these goods. These products are considered safe and effective in cats and dogs by the US Food and Drug Administration. To be used on animals, however, isoxazoline medications must be licenced by the US FDA, EMA, and Canada Health.
The US Food and Drug Administration issued a warning in September 2018 about flea medications and chews linked to neurological issues. In certain dogs and cats, these products cause neurological symptoms such as ataxia, seizures, and muscular tremors. To some extent, these laws limit the commercial expansion of these medications.
Pet owners and veterinarians are being polled by pharma companies about the use and safety of isoxazoline treatments. According to these surveys, isoxazoline neurotoxicity was not limited to ticks and fleas. The makers have revised the labelling for several medications as a result of these studies. Isoxazoline medicines, on the other hand, are considered safe and effective for cats and dogs by the US FDA.
Based on product type, the worldwide isoxazoline Drugs Market is divided into fluralaner, sarolaner, lotilaner, and afoxolaner. In 2021, afoxolaner medicines sold more than any other drug on the market, and they had the biggest market share.
The market is divided into two categories: dogs and cats. During the years 2020–2021, the number of dogs and cats adopted skyrocketed. According to a poll performed by the Humane Society of the United States, over half of all American households own at least one dog. The dogs' category took the bulk of the market share in 2021 and is predicted to increase at a CAGR of 18.11% during the forecast period.
The European Medicines Agency (EMA) and the European Commission granted Boehringer Ingelheim marketing permission for NexGard COMBO topical solution for cats in January 2021.
Boehringer Ingelheim will offer NexGard, a tick and flea repellent, in India in July 2020.
Boehringer Ingelheim stated in November 2018 that they had acquired clearance to broaden the label claims for NexGard to include the treatment of two serious skin disorders in dogs. In Australia and Europe, these new approvals involve the treatment of cutaneous illnesses such as demodicosis and sarcoptic mange.